Alto Neuroscience

About:

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

Website: https://www.altoneuroscience.com

Twitter/X: altoneuro

Top Investors: Eli Lilly, Stanford University, Franklin Templeton, Point72 Ventures, Alexandria Venture Investments

Description:

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.

Total Funding Amount:

$239M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Los Altos, California, United States

Founded Date:

2019-01-01

Contact Email:

info(AT)altoneuroscience.com

Founders:

Amit Etkin, Dan Segal, Wei Wu

Number of Employees:

11-50

Last Funding Date:

2023-11-21

IPO Status:

Public

© 2024 MyAiNote.com